Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5

US6994852B1 · kind B1 · utility

Assignees

• Temple University-Of The Commonwealth System of Higher Education · US
• Bristol-Myers Squibb Pharma Company · US

Inventors

• Robert W. Colman · Moylan, US
• Shaker A. Mousa · McKeesport, US

Key dates

• Filing date: Nov 10, 2000
• Grant date: Feb 7, 2006
• Expiry date: Oct 22, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.